(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 1,457.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.72%.
Argenx Se's revenue in 2025 is $1,917,647.On average, 31 Wall Street analysts forecast ARGX's revenue for 2025 to be $262,691,205,408, with the lowest ARGX revenue forecast at $241,756,474,122, and the highest ARGX revenue forecast at $307,917,549,090. On average, 31 Wall Street analysts forecast ARGX's revenue for 2026 to be $359,613,518,184, with the lowest ARGX revenue forecast at $268,611,523,002, and the highest ARGX revenue forecast at $437,371,091,532.
In 2027, ARGX is forecast to generate $438,652,809,774 in revenue, with the lowest revenue forecast at $337,641,205,464 and the highest revenue forecast at $580,252,158,414.